Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of “Buy” by Analysts

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) have been given a consensus rating of “Buy” by the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, fifteen have given a buy recommendation and five have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $78.9412.

A number of analysts recently commented on the stock. Truist Financial upgraded shares of Revolution Medicines to a “strong-buy” rating in a report on Wednesday. UBS Group started coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating for the company. Evercore raised Revolution Medicines to a “strong-buy” rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Finally, Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $92.51 on Friday. The business’s 50-day moving average price is $100.37 and its 200 day moving average price is $78.70. The firm has a market cap of $18.33 billion, a P/E ratio of -15.65 and a beta of 0.99. Revolution Medicines has a 52-week low of $29.17 and a 52-week high of $124.49. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the business earned ($1.12) EPS. As a group, sell-side analysts predict that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Xiaolin Wang sold 2,010 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares of the company’s stock, valued at $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Stephen Michael Kelsey sold 4,302 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the transaction, the insider owned 295,398 shares of the company’s stock, valued at $29,386,193.04. This trade represents a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 149,592 shares of company stock valued at $15,010,732 over the last 90 days. 8.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently made changes to their positions in the company. General Atlantic L.P. purchased a new stake in shares of Revolution Medicines in the 3rd quarter valued at approximately $115,556,000. Norges Bank purchased a new position in Revolution Medicines during the 4th quarter worth approximately $195,568,000. Avoro Capital Advisors LLC purchased a new position in Revolution Medicines during the 4th quarter worth approximately $172,840,000. UBS Group AG raised its stake in Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock valued at $245,954,000 after purchasing an additional 1,998,972 shares during the period. Finally, Polar Capital Holdings Plc lifted its holdings in shares of Revolution Medicines by 321.2% in the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock valued at $160,398,000 after purchasing an additional 1,535,686 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.